118 related articles for article (PubMed ID: 22825819)
1. Seroprevalence of neutralizing antibodies to human adenovirus type 5 in healthy adults in China.
Yu B; Zhou Y; Wu H; Wang Z; Zhan Y; Feng X; Geng R; Wu Y; Kong W; Yu X
J Med Virol; 2012 Sep; 84(9):1408-14. PubMed ID: 22825819
[TBL] [Abstract][Full Text] [Related]
2. Epidemiology of adenovirus type 5 neutralizing antibodies in healthy people and AIDS patients in Guangzhou, southern China.
Sun C; Zhang Y; Feng L; Pan W; Zhang M; Hong Z; Ma X; Chen X; Chen L
Vaccine; 2011 May; 29(22):3837-41. PubMed ID: 21447314
[TBL] [Abstract][Full Text] [Related]
3. International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials.
Mast TC; Kierstead L; Gupta SB; Nikas AA; Kallas EG; Novitsky V; Mbewe B; Pitisuttithum P; Schechter M; Vardas E; Wolfe ND; Aste-Amezaga M; Casimiro DR; Coplan P; Straus WL; Shiver JW
Vaccine; 2010 Jan; 28(4):950-7. PubMed ID: 19925902
[TBL] [Abstract][Full Text] [Related]
4. Seroprevalence of neutralizing antibodies to human adenoviruses type-5 and type-26 and chimpanzee adenovirus type-68 in healthy Chinese adults.
Zhang S; Huang W; Zhou X; Zhao Q; Wang Q; Jia B
J Med Virol; 2013 Jun; 85(6):1077-84. PubMed ID: 23588735
[TBL] [Abstract][Full Text] [Related]
5. Seroprevalence of neutralizing antibodies against adenovirus type 14 and 55 in healthy adults in Southern China.
Zheng X; Rong X; Feng Y; Sun X; Li L; Wang Q; Wang M; Liu W; Li C; Yang Y; Zhou R; Lu J; Feng L; Chen L
Emerg Microbes Infect; 2017 Jun; 6(6):e43. PubMed ID: 28588291
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of serum neutralizing antibodies to adenovirus type 5 (Ad5) and 41 (Ad41) in children is associated with age and sanitary conditions.
Yang WX; Zou XH; Jiang SY; Lu NN; Han M; Zhao JH; Guo XJ; Zhao SC; Lu ZZ
Vaccine; 2016 Nov; 34(46):5579-5586. PubMed ID: 27682509
[TBL] [Abstract][Full Text] [Related]
7. Neutralizing antibodies against adenovirus type 2 in normal and HIV-1-infected subjects: Implications for use of Ad2 vectors in vaccines.
Li Q; Liu Q; Huang W; Song A; Zhao C; Wu J; Wang Y
Hum Vaccin Immunother; 2017 Jun; 13(6):1-8. PubMed ID: 28301274
[TBL] [Abstract][Full Text] [Related]
8. The prevalence of neutralizing antibodies against AAV serotype 1 in healthy subjects in China: implications for gene therapy and vaccines using AAV1 vector.
Liu Q; Huang W; Zhao C; Zhang L; Meng S; Gao D; Wang Y
J Med Virol; 2013 Sep; 85(9):1550-6. PubMed ID: 23852678
[TBL] [Abstract][Full Text] [Related]
9. Seroepidemiological investigation of HAdV-4 infection among healthy adults in China and in Sierra Leone, West Africa.
Wang B; Li J; Wu S; Chen Y; Zhang Z; Zhai Y; Guo Q; Zhang J; Song X; Zhao Z; Hou L; Chen W
Emerg Microbes Infect; 2018 Dec; 7(1):200. PubMed ID: 30514848
[TBL] [Abstract][Full Text] [Related]
10. A serological survey of human adenovirus serotype 2 and 5 circulating pediatric populations in Changchun, China, 2011.
Yu B; Wang Z; Dong J; Wang C; Gu L; Sun C; Kong W; Yu X
Virol J; 2012 Nov; 9():287. PubMed ID: 23176136
[TBL] [Abstract][Full Text] [Related]
11. Seroprevalence of neutralizing antibodies to adenovirus type 5 among children in India: implications for recombinant adenovirus-based vaccines.
Appaiahgari MB; Pandey RM; Vrati S
Clin Vaccine Immunol; 2007 Aug; 14(8):1053-5. PubMed ID: 17596429
[TBL] [Abstract][Full Text] [Related]
12. Neutralizing antibodies to human and simian adenoviruses in humans and New-World monkeys.
Ersching J; Hernandez MI; Cezarotto FS; Ferreira JD; Martins AB; Switzer WM; Xiang Z; Ertl HC; Zanetti CR; Pinto AR
Virology; 2010 Nov; 407(1):1-6. PubMed ID: 20797754
[TBL] [Abstract][Full Text] [Related]
13. The prevalence of neutralising antibodies to chimpanzee adenovirus type 6 and type 7 in healthy adult volunteers, patients with chronic hepatitis B and patients with primary hepatocellular carcinoma in China.
Jian L; Zhao Q; Zhang S; Huang W; Xiong Y; Zhou X; Jia B
Arch Virol; 2014 Mar; 159(3):465-70. PubMed ID: 24057756
[TBL] [Abstract][Full Text] [Related]
14. Age dependence of adenovirus-specific neutralizing antibody titers in individuals from sub-Saharan Africa.
Thorner AR; Vogels R; Kaspers J; Weverling GJ; Holterman L; Lemckert AA; Dilraj A; McNally LM; Jeena PM; Jepsen S; Abbink P; Nanda A; Swanson PE; Bates AT; O'Brien KL; Havenga MJ; Goudsmit J; Barouch DH
J Clin Microbiol; 2006 Oct; 44(10):3781-3. PubMed ID: 17021110
[TBL] [Abstract][Full Text] [Related]
15. The sero-prevalence of anti-adenovirus 5 neutralizing antibodies is independent of a chronic hepatitis B carrier state in China.
Huang D; Hennequi M; Elvachev A; Menguy T; Silvestre N; Yu D; Han Y; Inchauspé G; Zhang X; Zhu R
Arch Virol; 2015 Apr; 160(4):1125-30. PubMed ID: 25616844
[TBL] [Abstract][Full Text] [Related]
16. The prevalence of antibodies to adenovirus serotype 5 in an adult Indian population and implications for adenovirus vector vaccines.
Pilankatta R; Chawla T; Khanna N; Swaminathan S
J Med Virol; 2010 Mar; 82(3):407-14. PubMed ID: 20087930
[TBL] [Abstract][Full Text] [Related]
17. Seroprevalence of Neutralizing Antibodies against Human Adenovirus Type-5 and Chimpanzee Adenovirus Type-68 in Cancer Patients.
Zhao H; Xu C; Luo X; Wei F; Wang N; Shi H; Ren X
Front Immunol; 2018; 9():335. PubMed ID: 29563911
[TBL] [Abstract][Full Text] [Related]
18. Novel replication-incompetent vector derived from adenovirus type 11 (Ad11) for vaccination and gene therapy: low seroprevalence and non-cross-reactivity with Ad5.
Holterman L; Vogels R; van der Vlugt R; Sieuwerts M; Grimbergen J; Kaspers J; Geelen E; van der Helm E; Lemckert A; Gillissen G; Verhaagh S; Custers J; Zuijdgeest D; Berkhout B; Bakker M; Quax P; Goudsmit J; Havenga M
J Virol; 2004 Dec; 78(23):13207-15. PubMed ID: 15542673
[TBL] [Abstract][Full Text] [Related]
19. Seroprevalence of Neutralizing Antibodies against Six Human Adenovirus Types Indicates the Low Level of Herd Immunity in Young Children from Guangzhou, China.
Tian X; Fan Y; Wang C; Liu Z; Liu W; Xu Y; Mo C; You A; Li X; Rong X; Zhou R
Virol Sin; 2021 Jun; 36(3):373-381. PubMed ID: 33165772
[TBL] [Abstract][Full Text] [Related]
20. Adenovirus serotype 5-specific neutralizing antibodies target multiple hexon hypervariable regions.
Bradley RR; Maxfield LF; Lynch DM; Iampietro MJ; Borducchi EN; Barouch DH
J Virol; 2012 Jan; 86(2):1267-72. PubMed ID: 22072746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
